图书馆订阅: Guest
Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集
肿瘤形成评论综述™
SJR: 0.631 SNIP: 0.503 CiteScore™: 2

ISSN 打印: 0893-9675
ISSN 在线: 2162-6448

肿瘤形成评论综述™

DOI: 10.1615/CritRevOncog.v17.i4.40
pages 345-359

Current Status of Radiosensitizing Agents for the Management of Rectal Cancer

Henrik Illum
Department of Hematology Oncology, Assistant Professor of Medicine, University of Texas Southwestern, 4500 S. Lancaster Road, Dallas, TX 75216

ABSTRACT

The management of locally advanced rectal cancer requires a multidisciplinary effort. Surgical resection remains the therapeutic cornerstone, but neoadjuvant chemoradiation clearly improves both surgical and long-term outcomes. Pathological complete response is a desirable outcome and has been associated with good long-term outcomes. This article provides an overview of the evolution and current role of radiosensitizing chemotherapy when given as part of neoadjuvant chemoradiation for locally advanced rectal cancer. 5-fluorouracil, given either as an infusion or orally as capecitabine, appears to have the most favorable balance of efficacy and tolerability at the present time. Oral administration without need for central IV access makes capecitabine an attractive option. Oxaliplatin and irinotecan have demonstrated increased toxicity without substantial associated improvement in outcomes. Both bevacizumab and cetuximab appear feasible when given with radiosensitizing chemotherapy, but no strong signal of improved efficacy has been demonstrated so far. There is currently a great need for new radiosensitizing agents and predictive biomarkers to help optimize the use of existing therapeutics. Increased topoisomerase I expression and increased EGFR gene copy number as possible predictors of response to irinotecan- and cetuximab-based chemoradiation, respectively, deserve further studies.


Articles with similar content:

Small RNAs: The Qualified Candidates for Gene Manipulation in Diverse Clinical Pathologies
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.31, 2014, issue 4
Gaurav Sharma, Kanwaljit Chopra, Indu Pal Kaur, Parveen Rishi, Sanjeev Puri
Pancreatic Cancer: Recent Advances in Nanoformulation-Based Therapies
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.36, 2019, issue 1
Preshita Desai, Jeffrey Wang, Sunil Prabhu, David Ann
Development of Nanoscale Approaches for Ovarian Cancer Therapeutics and Diagnostics
Critical Reviews™ in Oncogenesis, Vol.19, 2014, issue 3-4
Magnus Bergkvist, Sarah A. Engelberth, Nadine Hempel
Current Perspectives of Exosomes as Therapeutic Targets and Drug Delivery Vehicles for Pancreatic Cancer
Critical Reviews™ in Oncogenesis, Vol.24, 2019, issue 2
Rama Rao Malla, Deepak KGK, L. Srinivas, Deepthi S
Predictive Biomarkers for Response to Therapy in Advanced Colorectal/Rectal Adenocarcinoma
Critical Reviews™ in Oncogenesis, Vol.17, 2012, issue 4
Payal Kapur